Appointment of Secretarial Auditor for a term of Five (5) consecutive years subject to shareholders approval at the ensuing AGM
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's Board of Directors, at its meeting on May 9, 2025, approved the appointment of M/s. MK Saraf & Associates LLP, a peer-reviewed firm of practicing Company Secretaries, as the company's Secretarial Auditor. The appointment is for a term of 5 consecutive years, covering FY 2025-26 through FY 2029-30 (April 1, 2025 to March 31, 2030). The appointment and remuneration are subject to shareholder approval at the upcoming Annual General Meeting. The firm has experience in corporate law, SEBI regulations, and conducting secretarial audits, and holds ICSI peer review certification.
This is a routine compliance-related appointment with no direct impact on shareholders or the stock price. It simply fulfills regulatory requirements under SEBI LODR Regulations for periodic secretarial audit, which is mandatory for listed companies.